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NVA'-CYCLOSPORINE (NVa'-CsA) is 
a structural analogue of cyclosporine 
(CsA) with marked immunosuppressive activ-
ity.I-) NVa2-CsA appears to be less nephro-
toxic when compared with CsA in rodent 
models.' During efficacy studies in canine 
orthotopic liver allograf~s. equal doses of 
NVa 2-CsA and CsA produced significantly 
different blood concentrations. This observa-
tion prompted us to evaluate the comparative 
pharmacokinetics of NVa2-CsA and CsA in 
dogs. 
METHODS 
Male beagle dogs weighing between I I to 15 kg 
received in a sequential manner CsA or NVa1·CsA intra· 
venously as an inrusion over one hour (2 mg/kg) or orally 
(20 mg/kg) as an olive oil solution on four separate 
occasions. Drug solutions were administered after an 
overnight fast while water was allowed at libitum. Hepa· 
rinized blood samples were obtained at O. 0.25, 0.5. 1.2,3. 
4,6,8, 12.24. 36.48. and 72 hours after drug administra-
tion. Whole blood concentrations of NVa1·CsA and CsA 
were measured by high'performance liquid chromatogra-
phy (HPlC) as described earlier.'" Pharmacokinetic 
parameters were calculated according to standard proce· 
dures. • 
RESULTS 
Following intravenous administration. the 
blood levels of CsA and NVa2-CsA declined in 
a muhiexponential manner. The mean termi-
nal disposition rate constant of NVa2-CsA 
(0.073 hours-I) was not significantly different 
from the mean disposition rate constant of 
CsA (0.119 hours-I). There were also no 
significant differences in the steady state vol-
ume of distribution of these two compounds. 
However. the mean (±SD) clearance of 
NVa 2-CsA (5.9 ± 0.7 mL/min/kg) was sig-
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nificantly smaller compared with the clear-
ance of CsA (8.4 ± 1.1 mL/min/kg). There 
was also less variability in the clearance of 
NVa 2-CsA as compared with the clearance of 
CsA. 
Following oral administration of equal 
doses. the blood concentrations of CsA were 
consistently higher than that of NVa2-CsA. 
The time for peak blood concentrations was 
not significantly different for the two com-
pounds. However. the mean (±SD) oral bio-
availability of NVa2-CsA was 8.4 ± 2.6% as 
compared with 18.2% ± 3.3% for CsA. 
DISCUSSION 
NVa1-CsA and CsA arc produced by the 
fungus Tolypodadillm inflowm Gams. 
NVa2-CsA differs from CsA in its structure in 
that the amino acid norvaline replaces the 
a-aminobutyric acid in position 2 of the cyclic 
polypeptide. This sm:lIl change in the struc-
ture has preserved the immunosuppressive 
activity of the compound in rats.J Recently. 
we have shown that in canine orthotopic liver 
allografts NVa2-CsA has similar immunosup-
pressive properties as CsA. with no function-
ally detectable toxicity affecting the liver or 
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kidney. NVa2-CsA has been reported to lack 
the nephrotoxicity. a limiting side effect of 
CsA in rats.· 
Since structural changes have been' 
reported to alter the pharmacokinetic profiles 
of drugs. we investigated the kinetics of CsA 
and NVal-CsA in the same group of animals. 
From our results it appears that small changes 
in the structure of CsA result in significant 
alterations in certain pharmacokinetic param-
eters. NVa7-CsA is more lipophilic than CsA 
and is cleared from the dogs less readily as 
compared with CsA. It is also absorbed to a 
lesser extent compared with CsA after a single 
oral dose. The blood levels of NVa1-CsA after 
chronic oral dosing is a function of both the 
absorption and elimination. Although de-
creased absorption will tend to produce lower 
blood levels. decreased elimination will tend to 
keep the levels higher as compared with CsA. 
Our studies also indicate that the extent of 
absorption of NVa2-CsA is highly variable 
between dogs. This is similar to the observa-
tions made with CsA. It is therefore essential 
to monitor the blood or plasma concentrations 
of NVa1-CsA in future efficacy and toxicity 
studies. 
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